Triazole-based compound as the candidate to develop a novel medicines to treat toxoplasmosis

Antimicrob Agents Chemother. 2014 Oct 6. pii: AAC.03832-14. [Epub ahead of print]

 

Dzitko K¹, Paneth A², Plech T³, Pawełczyk J⁴, Węglińska L³, Paneth P⁵.

 

This letter reports anti-Toxoplasma gondii activity of 3-(thiophen-2-yl)-1,2,4-triazole-5-thione. The compound displayed significant and reproducible anti-parasitic effects at non-toxic concentrations for the host cells, with experimentally determined IC₅₀ value at least thirty time better than the one of known chemotherapeutic sulfadiazine. Purine nucleoside phosphorylase was defined as probable target for anti-Toxoplasma activity of tested compound. These results provide the foundation for the future work to develop a new class of medicines to better treat toxoplasmosis.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

PMID:

25288090

[PubMed - as supplied by publisher]